Objective: We investigated the regulation of endothelin-1 (ET-1) expression in in vivo high-fat diet (HFD)-fed mice and in vitro cultured human aortic endothelial cells (HAECs). Methods: Male C57BL/6 mice were fed on standard chow, serum was prepared, and ET-1 levels were analyzed using an ELISA kit. Quantitative PCR was performed using iQ SYBR Green Supermix. Statistical significance was assessed using SPSS, with p < 0.05 considered significant. Results: The serum ET-1 content and endothelial expression of ET-1 mRNA were increased in the HFD-fed mice compared to the chow-fed control mice. Moreover, the mRNA expression of ET-1 was significantly increased in cultured HAECs in response to acute (< 24 h) and chronic (12–16 days) treatments with palmitic acid (PA), one of the most abundant saturated fatty acids in obesity. We found that the induction of ET-1 expression by PA was abolished by pretreating the cells with the endoplasmic reticulum (ER) stress inhibitor 4-phenylbutyric acid or the protein kinase C (PKC) inhibitor Gö 6850. Conclusion: Our findings demonstrate for the first time that PA increases ET-1 expression in endothelial cells through the induction of ER stress and the activation of PKC, providing novel mechanistic insights into the pathogenesis of obesity-associated hypertension and cardiovascular diseases.

Keywords:
Obesity, Palmitic acid, Endothelin-1, Endothelial cells, Endoplasmic reticulum stress, Protein kinase C
1.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME: Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116: 991–1006.
2.
Eckel RH: Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248–3250.
3.
Cohen DH, LeRoith D: Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012; 19:F27–F45.
4.
Golay A, Ybarra J: Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2005; 19: 649–663.
5.
Basen-Engquist K, Chang M: Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011; 13: 71–76.
6.
Kannel WB: Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis 1974; 17: 5–24.
7.
Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE: Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271–17276.
8.
Antic V, Kiener-Belforti F, Tempini A, Van Vliet BN, Montani JP: Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits. Am J Hypertens 2000; 13: 556–559.
9.
Rocchini AP: Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 2000; 10: 287–294.
10.
Cabandugama PK, Gardner MJ, Sowers JR: The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am 2017; 101: 129–137.
11.
Cardillo C, Campia U, Iantorno M, Panza JA: Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004; 43: 36–40.
12.
Parrinello G, Scaglione R, Pinto A, Corrao S, Cecala M, Di Silvestre G, Amato P, Licata A, Licata G: Central obesity and hypertension: the role of plasma endothelin. Am J Hypertens 1996; 9: 1186–1191.
13.
Böhm F, Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8–18.
14.
Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A: The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz) 2015; 63: 41–52.
15.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415.
16.
Levin ER: Endothelins. N Engl J Med 1995; 333: 356–363.
17.
Rodríguez-Pascual F, Busnadiego O, Lagares D, Lamas S: Role of endothelin in the cardiovascular system. Pharmacol Res 2011; 63: 463–472.
18.
Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325–415.
19.
Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Segarra M, Espígol-Frigolé G, Prieto-González S, Her-nández-Rodríguez J, Preciado S, Lavilla R, Cid MC: Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis 2017; 76: 1624–1634.
20.
Laghmani K, Preisig PA, Moe OW, Yanagisawa M, Alpern RJ: Endothelin-1/endothelin-B receptor-mediated increases in NHE3 activity in chronic metabolic acidosis. J Clin Invest 2001; 107: 1563–1569.
21.
Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999; 43: 300–307.
22.
Cogan MG: Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990; 15: 451–458.
23.
He P, Klein J, Yun CC: Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 2010; 285: 27869–27878.
24.
Schiffrin EL: State-of-the-art lecture. Role of endothelin-1 in hypertension. Hypertension 1999; 34(pt 2): 876–881.
25.
Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14(pt 2): 83S–89S.
26.
Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, De Mattia G: Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 1995; 44: 431–436.
27.
Kostov K, Blazhev A, Atanasova M, Dimitrova A: Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in pre-hypertensive and hypertensive patients with type 2 diabetes. Int J Mol Sci 2016; 17:E1182.
28.
Letizia C, Celi M, Cerci S, Scuro L, Delfini E, Subioli S, Caliumi C, D’Erasmo E: High circulating levels of adrenomedullin and endothelin-1 in obesity associated with arterial hypertension (in Italian). Ital Heart J Suppl 2001; 2: 1011–1015.
29.
Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA: Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011; 301:H689–H695.
30.
Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(suppl 3): 14–23.
31.
Langin D: Control of fatty acid and glycerol release in adipose tissue lipolysis. C R Biol 2006; 329: 598–607; discussion 653–655.
32.
de Jongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CD: Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 2004; 53: 2873–2882.
33.
Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetière P, Esch-wège E: High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998; 27: 808–813.
34.
Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T: A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 2005; 12: 138–142.
35.
Luo Y, Rana P, Will Y: Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci 2012; 129: 346–362.
36.
Boden G: Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 1998; 3:d169–d175.
37.
Abdelmagid SA, Clarke SE, Nielsen DE, Badawi A, El-Sohemy A, Mutch DM, Ma DW: Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PLoS One 2015; 10:e0116195.
38.
Ubhayasekera SJ, Staaf J, Forslund A, Bergsten P, Bergquist J: Free fatty acid determination in plasma by GC-MS after conversion to Weinreb amides. Anal Bioanal Chem 2013; 405: 1929–1935.
39.
Zhang Y, Xue R, Zhang Z, Yang X, Shi H: Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells. Lipids Health Dis 2012; 11: 1.
40.
Wei Y, Wang D, Topczewski F, Pagliassotti MJ: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006; 291:E275–E281.
41.
Rong X, Albert CJ, Hong C, Duerr MA, Chamberlain BT, Tarling EJ, Ito A, Gao J, Wang B, Edwards PA, Jung ME, Ford DA, Tontonoz P: LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metab 2013; 18: 685–697.
42.
Nishitoh H: CHOP is a multifunctional transcription factor in the ER stress response. J Biochem 2012; 151: 217–219.
43.
Lai S, Li Y, Kuang Y, Cui H, Yang Y, Sun W, Liu K, Chen D, Yan Q, Wen L: PKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity. Biosci Rep 2017; 37:BSR20170869.
44.
Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL: Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49: 1239–1248.
45.
Maeda S, Jesmin S, Iemitsu M, Otsuki T, Matsuo T, Ohkawara K, Nakata Y, Tanaka K, Goto K, Miyauchi T: Weight loss reduces plasma endothelin-1 concentration in obese men. Exp Biol Med (Maywood) 2006; 231: 1044–1047.
46.
Wang D, Wei Y, Pagliassotti MJ: Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006; 147: 943–951.
47.
Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE: Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 2006; 47: 2726–2737.
48.
Anderson EK, Hill AA, Hasty AH: Stearic acid accumulation in macrophages induces toll-like receptor 4/2-independent inflammation leading to endoplasmic reticulum stress-mediated apoptosis. Arterioscler Thromb Vasc Biol 2012; 32: 1687–1695.
49.
Bravo R, Parra V, Gatica D, Rodriguez AE, Torrealba N, Paredes F, Wang ZV, Zorzano A, Hill JA, Jaimovich E, Quest AF, Lavandero S: Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int Rev Cell Mol Biol 2013; 301: 215–290.
50.
Oslowski CM, Urano F: Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol 2011; 490: 71–92.
51.
Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, Mori K, Sadighi Akha AA, Raden D, Kaufman RJ: Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006; 4:e374.
52.
Sakaki K, Kaufman RJ: Regulation of ER stress-induced macroautophagy by protein kinase C. Autophagy 2008; 4: 841–843.
53.
Xu S, Nam SM, Kim JH, Das R, Choi SK, Nguyen TT, Quan X, Choi SJ, Chung CH, Lee EY, Lee IK, Wiederkehr A, Wollheim CB, Cha SK, Park KS: Palmitate induces ER calcium depletion and apoptosis in mouse podocytes subsequent to mitochondrial oxidative stress. Cell Death Dis 2015; 6:e1976.
54.
Yakubu MA, Leffler CW: Regulation of ET-1 biosynthesis in cerebral microvascular endothelial cells by vasoactive agents and PKC. Am J Physiol 1999; 276:C300–C305.
55.
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394–402.
56.
Baier-Bitterlich G, Überall F, Bauer B, Fresser F, Wachter H, Grunicke H, Utermann G, Altman A, Baier G: Protein kinase C-θ isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol Cell Biol 1996; 16: 1842–1850.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.